Sangamo shares take a big hit as investors react to setback for pioneering gene-editing tech
Sangamo $SGMO today released the first snapshots from two early-stage studies looking at the effect their first-generation gene editing technology has on two rare and lethal diseases — MPS I and II. And from it Sangamo CEO Sandy Macrae has reached two basic conclusions:
“It’s working and it’s not sufficient for a clinical benefit.”
That conclusion — along with Sangamo’s assertion that their zinc finger nuclease approach is safe — is driving a switch-up in the clinic, where the biotech is pursuing a historic attempt to engineer a breakthrough in gene-editing humans after years of animal research.
Basic subscription required
Unlock this story instantly and join 58,000+ biopharma pros reading Endpoints daily — and it's free.